Healthcare Bearish Stocks: Illumina (NASDAQ:ILMN), The Clorox Co (NYSE:CLX), Dyax Corp. (NASDAQ:DYAX), Alexion Pharmaceuticals (NASDAQ:ALXN)



Illumina (NASDAQ:ILMN) SVP Nicholas Naclerio unloaded 2,000 shares of Illumina stock in a transaction that occurred on Monday, March 17th. Illumina, Inc. (NASDAQ:ILMN) stock performance was -5.42% in last session and finished the day at $152.60. Traded volume was 4,483,791 million shares in the last session and the average volume of the stock remained 1.99 million shares. The beta of the stock remained 0.44. Illumina, Inc. (NASDAQ:ILMN) insider ownership is 1.30%.

Clorox (NYSE:CLX)‘s stock had its “neutral” rating reaffirmed byZacks in a research note issued to investors on Thursday,AnalystRatingsNetwork.com reports. The Clorox Co (NYSE:CLX) rose 0.19 percent to $87.54 yesterday on volume of 1.53 million shares. The intra-day range of the stock was $87.47 to $88.57. The Clorox Co (NYSE:CLX) has a market capitalization of $ 11.37 billion.

Analysts at Oppenheimer initiated coverage on shares of Dyax Corp. (NASDAQ:DYAX) in a research note on Friday. They set an “outperform” rating and a $14.00 price target on the stock. Separately, analysts at Leerink Swann downgraded shares of Dyax Corp. from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 27th. Dyax Corp. (NASDAQ:DYAX)’s stock on Mar 21, 2014 reported a decrease of -5.13% to the closing price of $8.88. Its fifty two weeks range is $2.26 -$10.99. The total market capitalization recorded $1.19 billion. The overall volume in the last trading session was 6,337,492 million shares. In its share capital, Dyax Corp. (NASDAQ:DYAX) has 119.57 million outstanding shares.

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) had its price target raised by analysts at UBS AG from $185.00 to $202.00. They now have a “buy” rating on the stock. On Friday, shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) dropped -7.99% to close the day at $159.79. Company return on investment (ROI) is 10.20% and its monthly performance is recorded as -10.76%. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) quarterly revenue growth is 24.21%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone